Analysis on the correlation of TP53 mutations and their different variant forms with the efficacy of first-line treatment of EGFR-TKIs in patients with advanced EGFR-sensitive mutant lung adenocarcinoma
LI Xiaofang
XI Chenglin
HUO Ran
FANG Guotao
SHANG Yanhong
Abstract：Objective To explore the correlation of TP53 mutations and their different variant forms with the efficacy of first-line treatment of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in patients with advanced EGFR-sensitive mutant lung adenocarcinoma.Methods The data from The Cancer Genome Atlas(TCGA)database was collected for bioinformatics analysis.The clinical data of 152 patients with advanced EGFR-sensitive mutant(19 Del or 21 L858R)lung adenocarcinoma who were admitted to Department of Medical Oncology,Affiliated Hospital of Hebei University from December 2017 to December 2022 were retrospectively analyzed.All the patients were treated with EGFR-TKIs.The correlation of TP53 mutations and their different variant forms with the efficacy of EGFR-TKIs was analyzed.Results Of the 152 patients included in the analysis,105 patients had EGFR-TP53 co-mutations.The patients with TP53 mutations had shorter progression-free survival(PFS)than those with TP53 wild-type.The patients with missense mutations,mutations in exons 5-8,disruptive mutations,and non-disruptive mutations had shorter PFS than those with TP53 wild-type.In the patients with EGFR-TP53 co-mutations,the patients with TP53 missense mutations had shorter PFS than those with non-missense mutations,and the patients with non-disruptive TP53 mutations had shorter PFS than those with disruptive TP53 mutations,and the patients with mutations in exons 5-8 had shorter PFS than those with mutations in exon 4/9/10.Conclusion The advanced EGFR-sensitive mutant lung adenocarcinoma patients with TP53 mutations who receive first-line treatment have shorter PFS than those with TP53 wild-type,suggesting that TP53 mutations are negative predictor of efficacy of EGFR-TKIs in the advanced EGFR-sensitive mutant lung adenocarcinoma patients.In the patients with EGFR-TP53 co-mutations,the patients with TP53 missense mutations,non-disruptive mutations,and mutations in exons 5-8 have shorter PFS.
Keywords：Epidermal growth factor receptor(EGFR)TP53 mutationsCo-mutationsLung adenocarcinomaPrognosis
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 1339-1346 )